Literature DB >> 16492776

Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.

Sung Hee Baek1, Kenneth A Ohgi, Charles A Nelson, Derek Welsbie, Charlie Chen, Charles L Sawyers, David W Rose, Michael G Rosenfeld.   

Abstract

The androgen receptor not only mediates prostate development but also serves as a key regulator of primary prostatic cancer growth. Although initially responsive to selective androgen receptor modulators (SARMs), which cause recruitment of the nuclear receptor-corepressor (N-CoR) complex, resistance invariably occurs, perhaps in response to inflammatory signals. Here we report that dismissal of nuclear receptor-corepressor complexes by specific signals or androgen receptor overexpression results in recruitment of many of the cohorts of coactivator complexes that permits SARMs and natural ligands to function as agonists. SARM-bound androgen receptors appear to exhibit failure to recruit specific components of the coactivators generally bound by liganded nuclear receptors, including cAMP response element-binding protein (CBP)/p300 or coactivator-associated arginine methyltransferase 1 (CARM1) to the SARM-bound androgen receptor, although still causing transcriptional activation of androgen receptor target genes. SARM-bound androgen receptors use distinct LXXLL (L, leucine; X, any amino acid) helices in the p160 nuclear receptor interaction domains that may impose selective allosteric effects, providing a component of the molecular basis of differential responses to different classes of ligands by androgen receptor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492776      PMCID: PMC1413901          DOI: 10.1073/pnas.0510842103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.

Authors:  X Hu; M A Lazar
Journal:  Nature       Date:  1999-11-04       Impact factor: 49.962

Review 2.  The coregulator exchange in transcriptional functions of nuclear receptors.

Authors:  C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

3.  Mechanism of corepressor binding and release from nuclear hormone receptors.

Authors:  L Nagy; H Y Kao; J D Love; C Li; E Banayo; J T Gooch; V Krishna; K Chatterjee; R M Evans; J W Schwabe
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

4.  Molecular determinants of nuclear receptor-corepressor interaction.

Authors:  V Perissi; L M Staszewski; E M McInerney; R Kurokawa; A Krones; D W Rose; M H Lambert; M V Milburn; C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

5.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.

Authors:  J Torchia; D W Rose; J Inostroza; Y Kamei; S Westin; C K Glass; M G Rosenfeld
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

Review 6.  Nuclear receptors in Sicily: all in the famiglia.

Authors:  T Perlmann; R M Evans
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

Authors:  C L Smith; Z Nawaz; B W O'Malley
Journal:  Mol Endocrinol       Date:  1997-06

8.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

9.  Regulation of transcription by a protein methyltransferase.

Authors:  D Chen; H Ma; H Hong; S S Koh; S M Huang; B T Schurter; D W Aswad; M R Stallcup
Journal:  Science       Date:  1999-06-25       Impact factor: 47.728

10.  The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1.

Authors:  C L Bevan; S Hoare; F Claessens; D M Heery; M G Parker
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

View more
  30 in total

1.  Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation.

Authors:  Eric Metzger; Na Yin; Melanie Wissmann; Natalia Kunowska; Kristin Fischer; Nicolaus Friedrichs; Debasis Patnaik; Jonathan M G Higgins; Noelle Potier; Karl-Heinz Scheidtmann; Reinhard Buettner; Roland Schüle
Journal:  Nat Cell Biol       Date:  2007-12-09       Impact factor: 28.824

2.  Functions of nuclear actin-binding proteins in human cancer.

Authors:  Xinyi Yang; Ying Lin
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

3.  Inhibition of androgen receptor and β-catenin activity in prostate cancer.

Authors:  Eugine Lee; Aviv Madar; Gregory David; Michael J Garabedian; Ramanuj Dasgupta; Susan K Logan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

Review 4.  Development of selective androgen receptor modulators (SARMs).

Authors:  Ramesh Narayanan; Christopher C Coss; James T Dalton
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

5.  Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.

Authors:  Azriel Schmidt; Donald B Kimmel; Chang Bai; Angela Scafonas; Sujane Rutledge; Robert L Vogel; Sheila McElwee-Witmer; Fang Chen; Pascale V Nantermet; Viera Kasparcova; Chih-Tai Leu; Hai-Zhuan Zhang; Mark E Duggan; Michael A Gentile; Paul Hodor; Brenda Pennypacker; Patricia Masarachia; Evan E Opas; Sharon A Adamski; Tara E Cusick; Jiabing Wang; Helen J Mitchell; Yuntae Kim; Thomayant Prueksaritanont; James J Perkins; Robert S Meissner; George D Hartman; Leonard P Freedman; Shun-ichi Harada; William J Ray
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

6.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.

Authors:  Chen-Lin Hsieh; Teng Fei; Yiwen Chen; Tiantian Li; Yanfei Gao; Xiaodong Wang; Tong Sun; Christopher J Sweeney; Gwo-Shu Mary Lee; Shaoyong Chen; Steven P Balk; Xiaole Shirley Liu; Myles Brown; Philip W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

8.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

9.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

10.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.